immunotherapy in early-stage tnbc - where do we stand?
Published 3 years ago • 299 plays • Length 3:28Download video MP4
Download video MP3
Similar videos
-
0:58
personalizing approaches in early-stage tnbc
-
1:29
takeaways on the management of early-stage tnbc
-
5:53
treating early-stage tnbc
-
1:27
what to do in patients with early-stage tnbc who have not achieved a pcr?
-
2:46
de-escalation of therapy in early-stage tnbc
-
2:05
treatment advances in tnbc
-
4:20
keynote-522: 5-year follow-up of pembrolizumab in triple-negative breast cancer
-
4:11
immunotherapy for tnbc: impassion130 & keynote-355
-
2:21
the challenges of treating early-stage tnbc
-
4:13
where does immuno-oncology fit in the treatment landscape of tnbc?
-
1:34
strategies to improve the response to immunotherapy in tnbc
-
1:39
encouraging developments in triple negative breast cancer immunotherapy
-
5:21
optimal neoadjuvant and adjuvant therapy for patients with early tnbc
-
3:09
keynote-522: neoadjuvant and adjuvant pembrolizumab for early tnbc
-
2:30
impassion130: immunotherapy for tnbc
-
1:30
emerging immunotherapy beyond checkpoint inhibitors for tnbc
-
4:20
keynote 522: pembrolizumab as neoadjuvant treatment for early tnbc
-
3:17
multiplexed analysis and spatial histology to predict response to immunotherapy in breast cancer
-
2:05
immunotherapy in breast cancer